Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada
University of Otago, Christchurch, New Zealand.
Ann Fam Med. 2018 Nov;16(6):515-520. doi: 10.1370/afm.2315.
Polypharmacy is a key clinical challenge for primary care. Drugs that should be prescribed for an intermediate term (longer than 3 months, but not indefinitely) that are not appropriately discontinued could contribute to polypharmacy. We named this type of prescribing . Commonly prescribed drugs with legacy prescribing potential include antidepressants, bisphosphonates, and proton pump inhibitors (PPIs). We evaluated the proportion of legacy prescribing within these drug classes.
We conducted a population-based retrospective cohort study using prospectively collected data from the McMaster University Sentinel and Information Collaboration (MUSIC) Primary Care Practice Based Research Network, located in Hamilton, Ontario. All adult patients (aged 18 or older) in the MUSIC data set during 2010-2016 were included (N = 50,813). We calculated rates of legacy prescribing of antidepressants (prescription longer than 15 months), bisphosphonates (longer than 5.5 years), and PPIs (longer than 15 months).
The proportion of patients having a legacy prescription at some time during the study period was 46% (3,766 of 8,119) for antidepressants, 14% (228 of 1,592) for bisphosphonates, and 45% (2,885 of 6,414) for PPIs. Many of these patients held current prescriptions. The mean duration of prescribing for all legacy prescriptions was significantly longer than that for non-legacy prescriptions ( <.001). Concurrent legacy prescriptions for both antidepressants and PPIs was common, signaling a potential prescribing cascade.
The phenomenon of legacy prescribing appears prevalent. These data demonstrate the potential of legacy prescribing to contribute to unnecessary polypharmacy, providing an opportunity for system-level intervention in primary care with enormous potential benefit for patients.
药物的长期使用(超过 3 个月但非无限期)而未合理停药,是基层医疗面临的主要挑战之一。我们将这种类型的处方命名为“legacy prescribing”。具有 legacy prescribing 潜在可能性的常用处方药物包括抗抑郁药、双磷酸盐和质子泵抑制剂 (PPIs)。我们评估了这些药物类别中 legacy prescribing 的比例。
我们使用安大略省汉密尔顿麦克马斯特大学监测和信息合作(MUSIC)基层医疗实践基础研究网络前瞻性收集的数据进行了一项基于人群的回顾性队列研究。该研究纳入了 MUSIC 数据集中 2010 年至 2016 年期间所有成年患者(年龄≥18 岁)(N=50813)。我们计算了抗抑郁药(处方超过 15 个月)、双磷酸盐(超过 5.5 年)和 PPIs(超过 15 个月)legacy prescribing 的发生率。
在研究期间的某个时间点,有 legacy 处方的患者比例为:抗抑郁药 46%(3766/8119),双磷酸盐 14%(228/1592),PPIs 45%(2885/6414)。其中许多患者仍在服用当前的处方药物。所有 legacy 处方的平均用药时间明显长于非 legacy 处方(<0.001)。抗抑郁药和 PPIs 的同时 legacy 处方很常见,这表明存在潜在的处方传递。
legacy prescribing 现象似乎很普遍。这些数据表明,legacy prescribing 有可能导致不必要的药物滥用,为初级保健系统干预提供了机会,这对患者有巨大的潜在益处。